Tekla Life Sciences Investors
HQL · NYSE
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $87 | $39 | $32 | $45 |
| % Growth | 120.1% | 23.6% | -29.2% | – |
| Cost of Goods Sold | $0 | $5 | $6 | $6 |
| Gross Profit | $87 | $18 | $26 | $39 |
| % Margin | 100% | 46.4% | 82.6% | 86.5% |
| R&D Expenses | $0 | $0 | -$0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $85 | -$5 | -$105 | $65 |
| % Margin | 98.4% | -13.3% | -328.3% | 143.3% |
| Other Income/Exp. Net | $87 | $28 | $0 | -$0 |
| Pre-Tax Income | $85 | $22 | -$105 | $65 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $85 | $22 | -$105 | $65 |
| % Margin | 98.4% | 56.8% | -328.3% | 143.3% |
| EPS | 3.04 | 0.79 | -4.07 | 2.66 |
| % Growth | 284.8% | 119.4% | -253% | – |
| EPS Diluted | 3.04 | 0.79 | -4.07 | 2.66 |
| Weighted Avg Shares Out | 28 | 28 | 26 | 24 |
| Weighted Avg Shares Out Dil | 28 | 28 | 26 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $28 | $3 | $4 |
| EBITDA | $87 | $50 | -$102 | $69 |
| % Margin | 100.6% | 126.8% | -318.9% | 152.5% |